Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.

Li, Dou-Dou; Tao, Zhong-Hua; Wang, Bi-Yun; Wang, Lei-Ping; Cao, Jun; Hu, Xi-Chun; Zhang, Jian

Li, Dou-Dou; Tao, Zhong-Hua; Wang, Bi-Yun; Wang, Lei-Ping; Cao, Jun; Hu, Xi-Chun; Zhang, Jian.

Afiliação

Li DD; Department of Medical Oncology; Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tao ZH; Department of Medical Oncology; Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wang BY; Department of Medical Oncology; Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wang LP; Department of Medical Oncology; Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cao J; Department of Medical Oncology; Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hu XC; Department of Medical Oncology; Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. xchu2009@hotmail.com.
Zhang J; Department of Medical Oncology; Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. syner2000@163.com.

NPJ Breast Cancer ; 8(1): 110, 2022 Sep 20.

Article em En | MEDLINE | ID: mdl-36127351

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: NPJ Breast Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China